Cholesterol and triglycerides is the main area connected here, and any felt benefit should be read together with the human evidence base.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.
Paper IDs and full lists are private. Only study types and summaries are shown.
CoQ10 supplementation does not reduce muscle pain in patients with statin myalgia and only 36% of patients complaining of statin myalgia develop symptoms during a randomized, double-blind crossover of statin vs placebo.
Significantly reduced cardiovascular mortality could be seen in those on selenium and coenzyme Q10 intervention and the protective action was not confined to the intervention period, but persisted during the follow-up period.
A 12-year follow-up of a group of healthy elderly participants that were supplemented with selenium and coenzyme Q10 for four years validated the results obtained in the 10-year evaluation and observed a significantly reduced risk for CV mortality in this grou
This double-blind parallel study provides evidences supporting the beneficial effects of Coenzyme Q10 and L-carnitine supplements on serum levels of lactate and migraine symptoms.
CRP and sP-selectin showed significant changes reflecting effects on inflammation and atherosclerosis in those given selenium and coenzyme Q10 combined, and a reduced cardiovascular mortality could be demonstrated in the active group, irrespective of biomarker
The results suggest that CoQ10 plus NADH supplementation for 8 weeks is safe and potentially effective in reducing max HR during a cycle ergometer test and also on fatigue in CFS.